Taken together, our studies provide a mechanism and indicate that Ets-1/GPX2 axis mediates sorafenib resistance in HCC, targeting of which in the future might help in ameliorating resistance and increasing sorafenib efficacy. This evidence concerns the gene ETS1 and hepatocellular carcinoma.